董事會欣然公告，近日，本集團核藥抗腫瘤診療板塊與北京橡鑫生物科技有限公司(「金 橡醫學」)合作開發的泌尿系統腫瘤早檢產品優愛®的首張商業化處方在上海復旦大學附 屬華東醫院落地，標誌著我國目前唯一獲批上市的甲基化+基因突變雙機制的尿路上皮 癌早檢產品正式進入臨床應用，為中國患者提供更精准的無創腫瘤診斷服務。 金橡醫學成立於 2018 年，依託獨家的生物標誌物發現平台，聚焦未滿足的臨床需求， 已形成「腫瘤早診早篩及監測、癌症患者精准醫學檢測、全球抗腫瘤藥企研發合作」三 大板塊業務佈局。公司核心產品優愛/優護系列產品涵蓋了尿路上皮癌早檢產品 (「優愛® 」)、尿路上皮癌複查產品(「優愛 MRD」)以及前列腺癌早檢產品(「優護」)， 三款產品均獲得了美國食品藥品監督管理局(Food and Drug Administration，FDA)突破性 醫療器械認定。本集團已獲得這三款核心產品在中國大陸的獨家商業化及聯合開發權益。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 持續關連交易 商業合作協議 商業合作協議 2025 年 4 月 25 日，本公司間接非全資附屬公司成都社泰與 Sirtex Medical US 訂立 商業合作協議，據此，各方可交替聘用另一方提供與醫療器械產品及放射性藥物產 品研發有關的若干服務，包括(i)按逐個項目提供諮詢及服務；和/或 (ii) 贊助研究和 開發項目，和/或 (iii) 招聘和員工。根據業務合作協議的對價每年不得超過 120 萬 美元。 上市規則之含義 於本公告日期，CDH Genetech 為一間於開曼群島成立之公司，其主要業務為投資控 股，由 CDH Fund V, L.P. （一間根據開曼群島法律成立之有限合夥企業）全資擁有， 其普通合夥人為 CDH V Holdings ...

以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 超长续航模式。 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 资本寒冬，一家上市Bi o t e c h也没有挂掉。 1 8A生物科技七年之痒，7 0家公司（含摘B）仍然整整齐齐，一家没少，即使市值最小 的北海康成账上现金仅剩1亿元，但管理层认为2025年有足够的营运资金，即使诺辉健 康复牌暂时没有进展，但离生死大限还有5个月。 中国创新药处于少年时代，（在上市公司层面）有着足够的容错率和包容度，如同《百 年孤独》中初创的"马孔多"，这里全是年轻人，没有死亡，自然没有墓地。 然而，站在中国创新药1 0年节点之上，两大蜕变还是发生了。 今 非 昔 比 ， 《 创 新 药 供 给 侧 改 革 》 （ 2021 年 7 月 ） 指 出 的 内 卷 和 泡 沫 ， 如 今 都 不 再 严 重。 一是行业主要矛盾的蜕变，从同质化竞争的内部矛盾，转为中国生物科技快速崛起与美 国维持生物科技创新领域领导地位之间的外部矛盾。 二是创 ...

Core Viewpoint - The announcement by the company regarding the approval of its fluticasone propionate nasal spray marks a significant step in breaking the market monopoly of foreign products in the domestic allergic rhinitis treatment sector [2]. Group 1: Product Development and Market Position - The fluticasone propionate nasal spray is the first domestic generic product to be launched in China and has been included in the national medical insurance and essential drug lists [2]. - The company has established itself as one of the leading firms in the domestic market for allergic rhinitis treatments, with a comprehensive product pipeline [2]. - The respiratory and critical care segment generated approximately HKD 1.71 billion in revenue last year, reflecting a nearly 27% year-on-year growth [2]. Group 2: Future Development Strategy - The company plans to continue its strategy of independent research and global expansion, focusing on developing a comprehensive product cluster for chronic airway diseases and critical care [3].

Core Viewpoint - The announcement of the approval of the fluticasone propionate nasal spray by Yuan Da Pharmaceutical marks a significant milestone for the company, as it is the first domestic generic version in China, expected to disrupt the market dominated by foreign products and provide more affordable treatment options for patients with allergic rhinitis [1][4]. Group 1: Market Opportunity - The fluticasone propionate nasal spray is a preferred treatment for allergic rhinitis in China, which has a high prevalence of approximately 17.6% among adults, translating to nearly 250 million patients [4][5]. - The nasal preparation market in China is projected to reach nearly 3.5 billion RMB in 2023, with a compound annual growth rate (CAGR) of 10.4% from 2019 to 2023 [4]. - The market for fluticasone propionate nasal spray is expected to reach 2.46 billion RMB by 2025, indicating substantial growth potential [4]. Group 2: Competitive Landscape - The current market for nasal corticosteroids is largely dominated by foreign companies, with Pfizer and Merck holding about half of the market share in 2023, highlighting a significant opportunity for domestic alternatives [5]. - Yuan Da Pharmaceutical's successful launch of the budesonide nasal spray, another first generic product, demonstrates the potential for domestic products to gain market share and disrupt foreign dominance [5][6]. Group 3: Product Pipeline and Innovation - Yuan Da Pharmaceutical has a comprehensive pipeline for allergic rhinitis treatments, including the upcoming Ryaltris® combination nasal spray, which is expected to meet the needs of patients with varying severity of allergic rhinitis [7][8]. - The company is also developing STC3141, an innovative product targeting sepsis, which has shown promising clinical results and addresses a significant unmet medical need in a market projected to reach 5.627 billion USD by 2030 [9]. - The focus on both self-developed and globally expanded research and development aims to solidify the company's position in the respiratory and critical care sectors [9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 本集團中國首仿的丙酸氟替卡松鼻噴霧劑獲批上市 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事會 (「董事會」)自願刊發。 董事會欣然公告，本集團開發的用於治療過敏性鼻炎的丙酸氟替卡松鼻噴霧劑近日獲得 中華人民共和國國家藥品監督管理局(「藥監局」)頒發的藥品註冊證書，該產品為中國首 仿上市產品，且已被納入國家醫保目錄和國家基本用藥目錄，此次，該產品的獲批上市是 本集團在呼吸及危重症領域的又一次重大研發進展。 中國是世界上過敏性鼻炎發病率最高的國家之一。根據中國相關流行病學調查結果，中國 成人過敏性鼻炎患病率約 17.6%，患病群體已近 2.5 億人口，患者群體龐大。中國過敏性 鼻炎診斷率僅37.3%，治療率為4 ...

Group 1 - The Hong Kong stock market saw significant gains in the innovative pharmaceutical sector, with companies like Nocera Biopharma, Xiansheng Pharmaceutical, and Ascentage Pharma-B rising over 12% [1] - Various ETFs related to innovative pharmaceuticals and biotechnology also experienced increases, with the E Fund Hang Seng Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF rising over 4% [1] - The overall positive sentiment in the pharmaceutical sector is attributed to favorable policies and clinical trial results from key companies [4][5] Group 2 - Major pharmaceutical companies are reporting positive clinical trial results, such as the successful Phase III study of orforglipron by Eli Lilly, which could lead to its global launch [4] - The Chinese National Medical Products Administration has accepted a new drug application for Zurletrectinib, a next-generation TRK inhibitor, indicating ongoing innovation in the sector [4] - Analysts suggest that the pharmaceutical sector's valuation is currently low, and there is potential for recovery and growth, particularly in the innovative drug space [5][6] Group 3 - The increase in tariffs on imports from the U.S. is expected to benefit domestic pharmaceutical companies by promoting local substitutes in areas like blood products and high-end medical devices [6] - The domestic innovation in drug development is progressing, with some products reaching world-class standards, which could further enhance the competitive landscape [6]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]

Core Insights - The company announced a significant breakthrough in the development of GPN02006, a global innovative radiolabeled drug conjugate (RDC) for diagnosing hepatocellular carcinoma (HCC) [1] - The clinical results of the investigator-initiated trial (IIT) were publicly presented at the Chengdu 2025 Future XDC New Drug Conference, marking a milestone in the company's oncology nuclear drug development efforts [1] - GPN02006 is expected to become the world's first RDC product targeting the GPC-3 marker for HCC diagnosis [1]

智通财经APP获悉，核药龙头再添重磅产品新进展！4月21日，远大医药(00512)公布其用于诊断肝细胞癌(HCC)的全球创新放射性核素偶联药物(RDC) GPN02006在中国开展的研究者发起的临床研究（IIT临床研究）取得了里程碑式突破，并于成都2025未来XDC新药大会中公开发表了临床结果—— GPN02006给药后30分钟即可实现高质量显像，其显像背景信号极低，可实现HCC病灶特异性高摄取，且拥有优异的诊断对比度，临床优势显著。 GPN02006可为临床医生制定个体化诊疗方案提供强有力的分子影像学依据，充分满足肝细胞癌临床快速诊断需求，并有望改善当前HCC患者早期诊断率不 足及复发转移监测困难的临床现状。 此次研究进展标志着远大医药在抗肿瘤核药研发领域再次取得重大突破，进一步巩固了公司在放射性诊疗一体化领域的领先地位。 前瞻性布局GPC-3靶点，积极临床结果体现产品潜力 根据公告，GPN02006是远大医药合作开发的全球创新、基于放射性核素-抗体偶联技术的靶向磷脂酰肌醇蛋白聚糖3 (GPC-3)的诊断型放射性药物，其对 GPC-3靶点具有高特异性和高亲和力，且安全性好，适用对HCC的精准诊断，GPC3在 ...